Source Newsroom: Wake Forest University
Mar. 6, 2014 - The birth of a protein is one of the most fundamental aspects of life as we know it, yet, surprisingly, there is still a lot that scientists do not know about them.
Now split-second snapshots of this vital and mysterious process, developed by Samuel Cho, an assistant professor of physics and computer science, and senior Jessica Leuchter (’14), could someday lead to more effective antibiotics.
The birth of a protein
Proteins are the worker bees of cells. They get rid of waste, transmit cellular signals and carry out the chemical reactions that enable the human body to function. Without proteins, cells would be unable to function, replicate, and die.
This is not always a bad thing though, said Leuchter, a chemistry major who has been conducting research with Cho for two years. Viruses, bacteria and cancer cells need proteins to reproduce like everything else living in the human body.
Considering a 2013 CDC report noted that more than 2 million people get sick and roughly 23,000 people die each year as a result of drug-resistant bacterial infections, a new drug that could specifically target and halt protein formation in these malignant organisms would be a powerful tool for combatting diseases.
The problem with creating such a drug is scientists know very little about the microscopic environmental conditions and structures involved in creating proteins. This lack of awareness makes it difficult to identify targets inside a cell that drugs can be designed to attack.
Cho explained this is mostly due to the fact protein formation takes place at an incredibly small scale.
“Imagine the smallest thing you can think of and this is probably a lot smaller than that,” Cho said. “The entire process occurs in a space 100 billion trillionth the size of a water droplet. Even the best microscopes we have are not powerful enough to study this in the lab.”
Taking a closer look
This is where Cho and Leuchter’s work comes in. They created a computer model that simulates a required protein called Methionyl-tRNA Synthetase at one of the very first stages of protein formation in an E. coli bacteria cell. Their model enables them to accurately simulate processes at the molecular scale and identify and characterize previously unknown structures and crucial details of the chemical reactions that can then be used as drug targets. Then, an experimentalist can verify the targets Cho and Leuchter identify as critical in the lab.
“Thankfully we have a collaborator in the chemistry department who is the foremost expert on Methionyl-tRNA Synthetase, Rebecca Alexander,” Cho said. “It’s really nice having the authority on the subject in the next building so that she can say yes we have identified a new target or no we haven’t.”
New ways to fight disease
Cho said the next step in the research will be to tweak the computer model so it can be used to examine other proteins.
“What if we could turn important reactions off in the bacteria?” Cho asked. “A clearer picture of what is actually going on inside a cell will help us figure out what is an important interaction in terms of making proteins and what isn’t.”